Jason Minio

Cooley advised General Catalyst Partners, a venture capital firm providing early-stage and growth equity investments, as the lead investor in Helsing’s 209 million euro Series B financing.

Cooley advised customer engagement platform Braze on its $572 million initial public offering of 8,800,000 shares of Class A common stock, which now trade on the Nasdaq Global Select Market under the symbol BRZE. Lawyers Nicole Brookshire, Jodie Bourdet, Peter Byrne and Owen Williams led the team advising Braze.

Cooley advised Ovid on its $75 million initial public offering of 5,000,000 shares of common stock. Ovid, which now trades on The NASDAQ Global Select Market as “OVID,” is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders.

Cooley advised Opthea, a biopharmaceutical company focused on therapies for progressive retinal diseases, on its $128 million initial public offering of 8,563,300 American Depository Shares. The underwriters have the option to purchase up to an additional 1,425,000 shares. Partners Ferish Patel, Div Gupta, John McKenna and Brent Siler led the global Cooley team advising Opthea.

Cooley advised Vital Farms, a certified B Corporation and Delaware public benefit corporation that offers a range of ethically produced pasture-raised food products nationwide, on its $235.4 million initial public offering of 10,699,573 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. The transaction represents Cooley’s first completed IPO for a certified B Corporation. Partners Mike Lincoln, Nicole Brookshire, Darren DeStefano and Jaime Chase led the Cooley team advising Vital Farms.